20th‐Century Advances in Drug Therapy in Oncology—Part I

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of clinical pharmacology

• Publication date

  2000-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/00912700022009620PMID 10975071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.

  2009cited by this paper
• Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

  2005cited by this paper
• Phase II trial of idarubicin in patients with advanced lymphoma

  2004cited by this paper
• Pharmacokinetic monitoring of high-dose methotrexate

  2004cited by this paper
• Clinical pharmacology of oral thioguanine in acute myelogenous leukemia

  2004cited by this paper
• Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

  2001cited by this paper
• Cancer Chemotherapy and Biotherapy: Principles and Practice

  2001cited by this paper
• High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

  2000cited by this paper
• Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

  2000cited by this paper
• A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma

  2000cited by this paper
• Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.

  2000cited by this paper
• Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.

  2000cited by this paper
• Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.

  2000cited by this paper
• Deoxycoformycin in the treatment of patients with hairy cell leukemia

  2000cited by this paper
• Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

  2000cited by this paper
• Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.

  2000cited by this paper
• p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.

  2000cited by this paper
• EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

  2000cited by this paper
• A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma.

  2000cited by this paper
• Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.

  2000cited by this paper
• Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• A LONGITUDINAL STUDY OF CARDIAC FUNCTION IN CHILDREN WITH CANCER OVER 40 MONTHS

  2000cited by this paper
• Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.

  2000cited by this paper
• F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.

  2000cited by this paper
• Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

  1999cited by this paper
• Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

  1999cited by this paper
• Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy

  1999cited by this paper
• Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.

  1999cited by this paper
• Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: a prospective randomised trial.

  1999cited by this paper
• Taxanes: an overview of the pharmacokinetics and pharmacodynamics.

  1999cited by this paper
• Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.

  1999cited by this paper
• Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

  1999cited by this paper
• Long‐term follow‐up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine

  1999influential reference
• 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

  1999cited by this paper
• Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.

  1999cited by this paper
• Acquired activated protein C resistance in pregnancy is not due to elevated plasma caeruloplasmin levels

  1999cited by this paper
• Epirubicin

  1999cited by this paper
• A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.

  1999cited by this paper
• Monotherapy of metastatic breast cancer: a review of newer agents.

  1999cited by this paper
• Paclitaxel plus nonanthracycline combinations in metastatic breast cancer.

  1999cited by this paper
• Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.

  1999cited by this paper
• Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine

  1999cited by this paper
• Phase I study of liposomal vincristine.

  1999cited by this paper
• Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.

  1999cited by this paper
• A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.

  1999cited by this paper
• Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.

  1999cited by this paper
• Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.

  1999cited by this paper
• Management of small cell lung cancer.

  1999cited by this paper
• Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group.

  1999cited by this paper
• Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

  1999cited by this paper
• Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized hodgkin disease and unfavorable prognostic features

  1999cited by this paper
• Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

  1999cited by this paper
• Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.

  1999cited by this paper
• Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

  1999cited by this paper
• Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.

  1999cited by this paper
• Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.

  1999cited by this paper
• Pharmacokinetic Drug Interactions of Vinca Alkaloids: Summary of Case Reports

  1998cited by this paper
• Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

  1998cited by this paper
• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

  1998cited by this paper
• Phase I study of docetaxel with concomitant thoracic radiation therapy.

  1998cited by this paper
• Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.

  1998cited by this paper
• A southwest oncology group and cancer and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in Adults with advanced osteosarcoma, ewing's sarcoma, and rhabdomyosarcoma

  1998cited by this paper
• Severe vincristine toxicity in combination with itraconazole.

  1998cited by this paper
• Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

  1998cited by this paper
• Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.

  1998cited by this paper
• Preclinical pharmacokinetics of paclitaxel and docetaxel.

  1998cited by this paper
• CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

  1998cited by this paper
• Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.

  1998cited by this paper
• Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.

  1998cited by this paper
• Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.

  1998cited by this paper
• Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

  1998cited by this paper
• Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease.

  1998cited by this paper
• Chemotherapy of ovarian cancer.

  1998cited by this paper
• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.

  1998cited by this paper
• Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

  1997cited by this paper
• Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.

  1997cited by this paper
• Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.

  1997cited by this paper
• Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.

  1997cited by this paper
• Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

  1997cited by this paper
• Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.

  1997cited by this paper
• An overview of the clinical pharmacology of topotecan.

  1997cited by this paper
• Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.

  1997cited by this paper
• Clinical Pharmacokinetics of Irinotecan

  1997cited by this paper
• Doxorubicin plus paclitaxel in advanced breast cancer.

  1997cited by this paper
• Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.

  1997cited by this paper
• Paclitaxel pharmacology and other tumor types.

  1997cited by this paper
• Review of phase I clinical studies with topotecan.

  1997cited by this paper
• A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia

  1997cited by this paper
• Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.

  1996cited by this paper
• Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.

  1996cited by this paper
• Clinical Pharmacokinetics of Topotecan

  1996cited by this paper
• Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.

  1996cited by this paper

• Tumor-Associated Neutrophils in Cancer: Going Pro

  2019cites this paper
• Étude des implications biochimiques et moléculaires sous-jacentes à la pharmacothérapie ciblée contre la proprotéine convertase PACE4 dans le cancer de la prostate

  2018cites this paper
• Liposomal Bisphosphonates for the Treatment of Restenosis

  2016cites this paper
• Magnetic property, DFT calculation, and biological activity of bis[(μ(2)-chloro)chloro(1,10-phenanthroline)copper(II)] complex.

  2015cites this paper
• Pyrazolone incorporating bipyridyl metallointercalators as effective DNA, protein and lung cancer targets: Synthesis, characterization and in vitro biocidal evaluation.

  2015cites this paper
• Tumour vasculature targeting agents in hybrid/conjugate drugs

  2013cites this paper
• Lysosomotropic Properties of Weakly Basic Anticancer Agents Promote Cancer Cell Selectivity In Vitro

  2012cites this paper
• Intracellular drug distribution-based targeting: Exploiting lysosomes to enhance the selectivity of drugs towards cancer cells

  2012cites this paper
• Evaluation of human LOX-12 as a serum marker for breast cancer.

  2011cites this paper
• Structure-activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors.

  2011cites this paper
• Intracellular Distribution-based Anticancer Drug Targeting: Exploiting a Lysosomal Acidification Defect Associated with Cancer Cells.

  2010cites this paper
• The Role of Lysosomes in Limiting Drug Toxicity in Mice

  2010cites this paper
• Response of γδ T cells to plant-derived tannins

  2008cites this paper
• Actin- and Microtubule-Targeting Bioprobes: Their Binding Sites and Inhibitory Mechanisms

  2007cites this paper
• Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors.

  2007cites this paper
• Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

  2007cites this paper
• Anti-microtubule activity of tubeimoside I and its colchicine binding site of tubulin

  2007cites this paper
• Entrapment of drugs and other materials into liposomes

  2007influential citation
• Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.

  2007cites this paper
• Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors.

  2006cites this paper
• Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series.

  2006cites this paper
• 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.

  2002cites this paper
• The biology of neoadjuvant chemotherapy for breast cancer.

  2002cites this paper
• All-cause mortality Communicable diseases AIDS Tuberculosis Birth outcomes Infant mortality Low birthweight aCauses of death not included in the low-income / high-income disparities analysis

  2002cites this paper
• Evaluating Chicago's Success in Reaching the Healthy People 2000 Goal of Reducing Health Disparities

  2001cites this paper
• Pharmacognosy in the 21st century *

  2001cites this paper